Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786,
as compared with placebo, for the treatment of negative symptoms of schizophrenia.